Insulin patch pumps: their development and future in closed-loop systems.
Steady progress is being made toward the development of a so-called "artificial pancreas," which may ultimately be a fully automated, closed-loop, glucose control system comprising a continuous glucose monitor, an insulin pump, and a controller. The controller will use individualized algorithms to direct delivery of insulin without user input. A major factor propelling artificial pancreas development is the substantial incidence of-and attendant patient, parental, and physician concerns about-hypoglycemia and extreme hyperglycemia associated with current means of insulin delivery for type 1 diabetes mellitus (T1DM). A successful fully automated artificial pancreas would likely reduce the frequency of and anxiety about hypoglycemia and marked hyperglycemia. Patch-pump systems ("patch pumps") are likely to be used increasingly in the control of T1DM and may be incorporated into the artificial pancreas systems of tomorrow. Patch pumps are free of tubing, small, lightweight, and unobtrusive. This article describes features of patch pumps that have been approved for U.S. marketing or are under development. Included in the review is an introduction to control algorithms driving insulin delivery, particularly the two major types: proportional integrative derivative and model predictive control. The use of advanced algorithms in the clinical development of closed-loop systems is reviewed along with projected next steps in artificial pancreas development.
Medical Affairs, Animas Corporation, 200 Lawrence Drive, West Chester, PA 19380, USA hanhalt@its.jnj.com
Henry
H
Anhalt
Nancy J V
NJ
Bohannon
D000465:Algorithms; D001187:Artificial Organs; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D004867:Equipment Design / Q000592:standards; D005544:Forecasting; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use; D007332:Insulin Infusion Systems / Q000639:trends*; D040541:Marketing / Q000379:methods; D008904:Miniaturization / Q000379:methods; D008962:Models, Theoretical; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D007328:Insulin